Exelixis | EXEL - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Amgen USD 4.61B 777M 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
Bayer EUR 827M 2.7B 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Cytokinetics USD -179.17M 2.05M 2026-06
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Exelixis USD 248.41M 2.93M 2026-06
Genmab DKK 407M 182M 2026-06
Glaxosmithkline GBP 2.29B 3.08M 2026-03
Incyte USD 700.4M 376.22M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
MacroGenics USD -33.44M 21.34M 2026-03
Merck USD 840M 2.72B 2026-06
Moderna USD -815M 573M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Novartis USD 4.75B 515M 2026-06
Pfizer USD 667M 4.32B 2026-06
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sanofi EUR 2.27B 771M 2026-03
Takeda JPY 201.42B 215.04B 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Xencor USD -36.6M 41.26M 2026-06